136 related articles for article (PubMed ID: 20599922)
1. Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.
Mao Y; Zhang L; Jin J; Ashby B; Kunapuli SP
Eur J Pharmacol; 2010 Oct; 644(1-3):10-6. PubMed ID: 20599922
[TBL] [Abstract][Full Text] [Related]
2. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor.
Hoffmann K; Sixel U; Di Pasquale F; von Kügelgen I
Biochem Pharmacol; 2008 Nov; 76(10):1201-13. PubMed ID: 18809389
[TBL] [Abstract][Full Text] [Related]
3. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
4. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
Ding Z; Kim S; Dorsam RT; Jin J; Kunapuli SP
Blood; 2003 May; 101(10):3908-14. PubMed ID: 12560222
[TBL] [Abstract][Full Text] [Related]
6. A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor.
Jiang Q; Guo D; Lee BX; Van Rhee AM; Kim YC; Nicholas RA; Schachter JB; Harden TK; Jacobson KA
Mol Pharmacol; 1997 Sep; 52(3):499-507. PubMed ID: 9281613
[TBL] [Abstract][Full Text] [Related]
7. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
8. P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.
Van Kolen K; Slegers H
J Neurochem; 2004 Apr; 89(2):442-53. PubMed ID: 15056287
[TBL] [Abstract][Full Text] [Related]
9. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.
Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I
J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189
[TBL] [Abstract][Full Text] [Related]
10. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.
Schmidt P; Ritscher L; Dong EN; Hermsdorf T; Cöster M; Wittkopf D; Meiler J; Schöneberg T
Mol Pharmacol; 2013 Jan; 83(1):256-66. PubMed ID: 23093496
[TBL] [Abstract][Full Text] [Related]
11. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor.
Ding Z; Kim S; Kunapuli SP
Mol Pharmacol; 2006 Jan; 69(1):338-45. PubMed ID: 16234484
[TBL] [Abstract][Full Text] [Related]
12. Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.
Ramström S; Rånby M; Lindahl TL
Thromb Res; 2003 Mar; 109(5-6):315-22. PubMed ID: 12818256
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor.
Deflorian F; Jacobson KA
J Comput Aided Mol Des; 2011 Apr; 25(4):329-38. PubMed ID: 21461952
[TBL] [Abstract][Full Text] [Related]
14. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
15. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2005 May; 93(5):880-8. PubMed ID: 15886804
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Fox SC; Behan MW; Heptinstall S
Cell Calcium; 2004 Jan; 35(1):39-46. PubMed ID: 14670370
[TBL] [Abstract][Full Text] [Related]
17. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.
Moro S; Guo D; Camaioni E; Boyer JL; Harden TK; Jacobson KA
J Med Chem; 1998 Apr; 41(9):1456-66. PubMed ID: 9554879
[TBL] [Abstract][Full Text] [Related]
18. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.
Parravicini C; Ranghino G; Abbracchio MP; Fantucci P
BMC Bioinformatics; 2008 Jun; 9():263. PubMed ID: 18533035
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
20. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets.
Jagroop IA; Burnstock G; Mikhailidis DP
Platelets; 2003 Feb; 14(1):15-20. PubMed ID: 12623443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
